: In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests / Saponaro, M.; Annunziata, L.; Turla, A.; Vigano, I.; De Laurentiis, M.; Giuliano, M.; Del Mastro, L.; Montemurro, F.; Puglisi, F.; De Angelis, C.; Buono, G.; Schettini, F.; Arpino, G.. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 23:21(2022), p. 13604. [10.3390/ijms232113604]
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
De Laurentiis M.;Giuliano M.;De Angelis C.;
2022
Abstract
: In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
